About Bionovis sa
Bionovis SA: Pioneering the Production of Bio-Pharmaceuticals in Brazil
Bionovis SA is a Brazilian company that has been at the forefront of producing bio-pharmaceuticals in the country. The company has been instrumental in providing access to high-cost and complex medications to Brazilians through its partnership with SUS (Sistema Único de Saúde), which is Brazil's public health system.
The company was founded in 2012 as a joint venture between four major pharmaceutical companies, namely Aché Laboratórios Farmacêuticos S.A., EMS S/A, Hypera S.A., and União Química Farmacêutica Nacional S.A. Bionovis SA was established with the aim of developing and manufacturing biopharmaceutical products for the Brazilian market.
Since its inception, Bionovis SA has made significant strides in producing bio-pharmaceuticals that are essential for treating various diseases such as cancer, autoimmune disorders, and rare genetic conditions. The company's portfolio includes biosimilars - biological products that are similar to already approved drugs - as well as innovative biologics.
One of Bionovis' most notable achievements is its partnership with SUS. Through this collaboration, Bionovis provides access to high-quality medications at affordable prices to patients who would otherwise not be able to afford them. This partnership has helped improve healthcare outcomes for many Brazilians who suffer from chronic illnesses.
Bionovis' commitment to quality is evident through its state-of-the-art manufacturing facilities located in São Paulo and Bahia. These facilities adhere strictly to international standards such as Good Manufacturing Practices (GMP) and have received certifications from regulatory bodies such as ANVISA (Agência Nacional de Vigilância Sanitária).
In addition to its focus on quality production processes, Bionovis also invests heavily in research and development. The company has a team of highly skilled scientists and researchers who work tirelessly to develop new and innovative biopharmaceutical products that can help improve patient outcomes.
Bionovis' dedication to innovation has led to the development of several biosimilars, including Infliximab, Etanercept, Adalimumab, and Rituximab. These drugs have been approved by ANVISA and are now available in Brazil at significantly lower prices than their branded counterparts.
In conclusion, Bionovis SA is a pioneering company that has made significant contributions to the production of bio-pharmaceuticals in Brazil. Its commitment to quality production processes, research and development, as well as its partnership with SUS have helped improve healthcare outcomes for many Brazilians suffering from chronic illnesses. With its state-of-the-art manufacturing facilities and highly skilled team of scientists and researchers, Bionovis is poised to continue leading the way in producing high-quality biopharmaceutical products for the Brazilian market.